Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 363

1.

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.

Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, Lass-Flörl C, Lewis RE, Munoz P, Verweij PE, Warris A, Ader F, Akova M, Arendrup MC, Barnes RA, Beigelman-Aubry C, Blot S, Bouza E, Brüggemann RJM, Buchheidt D, Cadranel J, Castagnola E, Chakrabarti A, Cuenca-Estrella M, Dimopoulos G, Fortun J, Gangneux JP, Garbino J, Heinz WJ, Herbrecht R, Heussel CP, Kibbler CC, Klimko N, Kullberg BJ, Lange C, Lehrnbecher T, Löffler J, Lortholary O, Maertens J, Marchetti O, Meis JF, Pagano L, Ribaud P, Richardson M, Roilides E, Ruhnke M, Sanguinetti M, Sheppard DC, Sinkó J, Skiada A, Vehreschild MJGT, Viscoli C, Cornely OA.

Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38. doi: 10.1016/j.cmi.2018.01.002. Epub 2018 Mar 12.

2.

Invasive mould infections in the ICU setting: complexities and solutions.

Bassetti M, Bouza E.

J Antimicrob Chemother. 2017 Mar 1;72(suppl_1):i39-i47. doi: 10.1093/jac/dkx032. Review.

PMID:
28355466
3.

Managing invasive aspergillosis in haematological patients in the era of resistance polymerase chain reaction and increasing triazole resistance: A modelling study of different strategies.

van de Peppel RJ, van der Beek MT, Visser LG, de Boer MGJ, Wallinga J.

Int J Antimicrob Agents. 2019 Mar;53(3):284-293. doi: 10.1016/j.ijantimicag.2018.10.021. Epub 2018 Nov 2.

PMID:
30395989
4.

Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).

Mellinghoff SC, Panse J, Alakel N, Behre G, Buchheidt D, Christopeit M, Hasenkamp J, Kiehl M, Koldehoff M, Krause SW, Lehners N, von Lilienfeld-Toal M, Löhnert AY, Maschmeyer G, Teschner D, Ullmann AJ, Penack O, Ruhnke M, Mayer K, Ostermann H, Wolf HH, Cornely OA.

Ann Hematol. 2018 Feb;97(2):197-207. doi: 10.1007/s00277-017-3196-2. Epub 2017 Dec 7. Review.

5.

Characterization of patients with chronic pulmonary aspergillosis according to the new ESCMID/ERS/ECMM and IDSA guidelines.

Salzer HJ, Heyckendorf J, Kalsdorf B, Rolling T, Lange C.

Mycoses. 2017 Feb;60(2):136-142. doi: 10.1111/myc.12589. Epub 2016 Dec 1.

PMID:
27910139
6.

Our 2015 approach to invasive pulmonary aspergillosis.

Liss B, Vehreschild JJ, Bangard C, Maintz D, Frank K, Grönke S, Michels G, Hamprecht A, Wisplinghoff H, Markiefka B, Hekmat K, Vehreschild MJ, Cornely OA.

Mycoses. 2015 Jun;58(6):375-82. doi: 10.1111/myc.12319. Epub 2015 Mar 24. Review.

PMID:
25808916
7.

[Aspergillus in airway material : Ignore or treat?]

Salzer HJF, Lange C, Hönigl M.

Internist (Berl). 2017 Nov;58(11):1150-1162. doi: 10.1007/s00108-017-0334-9. Review. German.

PMID:
28986661
8.

A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility.

Mortensen KL, Johansen HK, Fuursted K, Knudsen JD, Gahrn-Hansen B, Jensen RH, Howard SJ, Arendrup MC.

Eur J Clin Microbiol Infect Dis. 2011 Nov;30(11):1355-63. doi: 10.1007/s10096-011-1229-7. Epub 2011 May 4.

PMID:
21541671
9.

ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013.

Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, Lanternier F, Pagano L, Skiada A, Akova M, Arendrup MC, Boekhout T, Chowdhary A, Cuenca-Estrella M, Freiberger T, Guinea J, Guarro J, de Hoog S, Hope W, Johnson E, Kathuria S, Lackner M, Lass-Flörl C, Lortholary O, Meis JF, Meletiadis J, Muñoz P, Richardson M, Roilides E, Tortorano AM, Ullmann AJ, van Diepeningen A, Verweij P, Petrikkos G; European Society of Clinical Microbiology and Infectious Diseases Fungal Infection Study Group; European Confederation of Medical Mycology.

Clin Microbiol Infect. 2014 Apr;20 Suppl 3:5-26. doi: 10.1111/1469-0691.12371.

10.

How to make a fast diagnosis in invasive aspergillosis.

Lass-Flörl C.

Med Mycol. 2019 Apr 1;57(Supplement_2):S155-S160. doi: 10.1093/mmy/myy103. Review.

PMID:
30816965
11.

Aspergillus tanneri sp. nov., a new pathogen that causes invasive disease refractory to antifungal therapy.

Sugui JA, Peterson SW, Clark LP, Nardone G, Folio L, Riedlinger G, Zerbe CS, Shea Y, Henderson CM, Zelazny AM, Holland SM, Kwon-Chung KJ.

J Clin Microbiol. 2012 Oct;50(10):3309-17. doi: 10.1128/JCM.01509-12. Epub 2012 Aug 1.

12.

Voriconazole-refractory invasive aspergillosis.

Park SY, Yoon JA, Kim SH.

Korean J Intern Med. 2017 Sep;32(5):805-812. doi: 10.3904/kjim.2017.109. Epub 2017 Aug 24. Review.

13.

Susceptibility Testing of Common and Uncommon Aspergillus Species against Posaconazole and Other Mold-Active Antifungal Azoles Using the Sensititre Method.

Mello E, Posteraro B, Vella A, De Carolis E, Torelli R, D'Inzeo T, Verweij PE, Sanguinetti M.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00168-17. doi: 10.1128/AAC.00168-17. Print 2017 Jun.

14.

Isavuconazole: Case Report and Pharmacokinetic Considerations.

Marchesi F, Girmenia C, Goffredo BM, Salvatorelli E, Romano A, Mengarelli A, Minotti G, Menna P.

Chemotherapy. 2018;63(5):253-256. doi: 10.1159/000494329. Epub 2018 Nov 20.

PMID:
30458443
15.

Comparison of the activities of amphotericin B, itraconazole, and voriconazole against clinical and environmental isolates of Aspergillus species.

Misra R, Malik A, Singhal S.

Indian J Pathol Microbiol. 2011 Jan-Mar;54(1):112-6. doi: 10.4103/0377-4929.77352.

16.

Changes in In Vitro Susceptibility Patterns of Aspergillus to Triazoles and Correlation With Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999-2015.

Heo ST, Tatara AM, Jiménez-Ortigosa C, Jiang Y, Lewis RE, Tarrand J, Tverdek F, Albert ND, Verweij PE, Meis JF, Mikos AG, Perlin DS, Kontoyiannis DP.

Clin Infect Dis. 2017 Jul 15;65(2):216-225. doi: 10.1093/cid/cix297.

17.

Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients.

Maschmeyer G, Haas A, Cornely OA.

Drugs. 2007;67(11):1567-601. Review.

PMID:
17661528
18.

Antifungal susceptibility of Aspergillus species isolated from invasive oral infection in neutropenic patients with hematologic malignancies.

Myoken Y, Sugata T, Myoken Y, Kyo T, Fujihara M, Mikami Y.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Feb;87(2):174-9.

PMID:
10052372
19.

Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: An illustrative case study.

Hoenigl M, Prattes J, Neumeister P, Wölfler A, Krause R.

Mycoses. 2018 Mar;61(3):201-205. doi: 10.1111/myc.12727. Epub 2017 Nov 22.

20.

Aspergillus pseudodeflectus: a new human pathogen in liver transplant patients.

Aït-Ammar N, Levesque E, Murat JB, Imbert S, Foulet F, Dannaoui E, Botterel F.

BMC Infect Dis. 2018 Dec 12;18(1):648. doi: 10.1186/s12879-018-3527-5.

Supplemental Content

Support Center